Ironwood Pharmaceuticals (IRWD) Return on Capital Employed (2011 - 2026)

Ironwood Pharmaceuticals (IRWD) has 16 years of Return on Capital Employed data on file, last reported at 111.57% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 9335.0% year-over-year to 111.57%; the trailing twelve-month figure through Mar 2026 stood at 111.57% (up 9335.0% YoY), and the FY2025 full-year result was 74.8%, up 4978.0% from the prior year.
• Return on Capital Employed advanced to 111.57% in Q1 2026, from 63.85% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 111.57% in Q1 2026 to a low of 491.1% in Q1 2024.
• A 5-year average of 48.57% and a median of 24.32% in 2022 frame the typical range for Return on Capital Employed.
• Across the five-year window, Return on Capital Employed slumped 51398 bps in 2024 and soared 50932 bps in 2025, its largest moves.
• Tracing IRWD's Return on Capital Employed over 5 years: stood at 23.96% in 2022, then plunged by 1882 bps to 426.89% in 2023, then surged by 107 bps to 28.1% in 2024, then surged by 127 bps to 63.85% in 2025, then surged by 75 bps to 111.57% in 2026.
• Business Quant data shows IRWD's Return on Capital Employed at 111.57% in Q1 2026, 63.85% in Q4 2025, and 97.0% in Q3 2025.